Streetbeat News

Earnings

IOBT

IO Biotech (NASDAQ:IOBT) reported a Q4 EPS loss of $(0.40), missing the consensus estimate of $(0.39) by 2.56%. However, this represents a 42.03% improvement over the $(0.69) loss per share from the same period last year.

Portfolio Pulse from Happy Mohamed

March 05, 2024 | 9:43 pm

CERS

Cerus Corporation projects its FY24 revenue to be between $172M and $175M, which is below the estimated $185.871M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:42 pm

FTEL

Fitell Corporation (NASDAQ:FTEL), an Australian online retailer of gym and fitness equipment, reported a significant decrease in H1 revenue and gross profit for the period ending December 31, 2023. Revenue fell by 30.5% to $2.1M, and gross profit dropped by 46.8% to $0.85M compared to the same period in 2022. The decline was attributed to decreased merchandise revenue, absence of sales in consumable products, and reduced licensing income. Despite a 34.3% increase in sales orders, the average revenue per order fell by 30.5%, mainly due to consumer spending changes. The company also faced increased expenses, including consulting fees and general and administrative costs, leading to a net loss of $2.66M, significantly higher than the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:41 pm

PKOH

Park-Ohio Holdings (NASDAQ:PKOH) reported Q4 earnings with an EPS of $0.54, missing estimates by -2.0% against an expected $0.55. Revenue increased by $7.70 million from the previous year. In contrast, the company had previously beaten EPS estimates in Q3 2023, leading to a 21.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:40 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced it will present preclinical data on CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for r/r AML, at the AACR Annual Meeting 2024. CB-012, engineered with Caribou's CRISPR technology, shows promise in improving antitumor activity through unique genome edits.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:38 pm

PKOH

Park-Ohio Holdings (PKOH) reported Q4 2023 adjusted EPS of $0.540, missing the $0.560 estimate, but sales of $389.3M exceeded the $386.45M estimate. This represents a 700% increase in EPS from the previous year and a 2.02% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:37 pm

BBAR

Banco BBVA Argentina reported a significant increase in its Q4 inflation-adjusted net income, showing a 220.8% rise quarter-over-quarter. However, on a year-over-year basis, the net income was 8.7% lower.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:37 pm

PSTV

Plus Therapeutics (NASDAQ:PSTV) reported Q4 earnings with a 35.0% beat on estimated EPS, reporting an EPS of $-0.7 versus an estimate of $-1.07. Revenue increased by $1.16 million from the same period last year. The company had previously beaten EPS estimates last quarter, which led to a 6.0% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:35 pm

NPCE

NeuroPace (NASDAQ:NPCE) reported Q4 earnings with an EPS of $-0.23, beating estimates by 26.0% and showing a revenue increase of $5.22 million from the previous year. Despite past earnings beats, such as last quarter's $0.13 EPS beat, the share price dropped 2.0% the following day. The company has consistently outperformed EPS estimates over the past four quarters.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:35 pm

RAPT

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced the acceptance of three late-breaking abstracts for presentation at the AACR Annual Meeting in April 2024, including phase 2 clinical data on tivumecirnon (FLX475) for head and neck squamous cell carcinoma. The presentations will cover the efficacy of FLX475 in combination with pembrolizumab, a combined mregDC and Treg signature's association with antitumor efficacy, and the role of HPK1 in CD8+ T cell effector gene expression.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:34 pm